|
TDRKH expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.7926994050631E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.03000052931179E-10 |
| Normal-vs-Stage2 |
3.020200E-01 |
| Normal-vs-Stage3 |
1.56170000042977E-07 |
| Normal-vs-Stage4 |
6.86709999975221E-07 |
| Stage1-vs-Stage2 |
6.817500E-03 |
| Stage1-vs-Stage3 |
9.967400E-01 |
| Stage1-vs-Stage4 |
6.301600E-01 |
| Stage2-vs-Stage3 |
1.400000E-02 |
| Stage2-vs-Stage4 |
1.201680E-02 |
| Stage3-vs-Stage4 |
6.887200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.61970437062564E-11 |
| Normal-vs-AfricanAmerican |
3.767700E-04 |
| Normal-vs-Asian |
4.13850000000604E-05 |
| Caucasian-vs-AfricanAmerican |
3.239200E-01 |
| Caucasian-vs-Asian |
8.940000E-01 |
| AfricanAmerican-vs-Asian |
4.310200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.28620000000324E-05 |
| Normal-vs-Female |
7.99293964348635E-12 |
| Male-vs-Female |
6.440200E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.8923002294905E-10 |
| Normal-vs-Age(41-60Yrs) |
4.05319999785547E-10 |
| Normal-vs-Age(61-80Yrs) |
1.304670E-03 |
| Normal-vs-Age(81-100Yrs) |
5.044000E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.955200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.782300E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.153970E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.430000E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.194450E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.084600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.056400E-01 |
| Classical-VS-Follicular |
4.80537831748507E-12 |
| Classical-VS-Other |
2.977600E-01 |
| Classical-VS-Normal |
9.99200722162641E-16 |
| Tall-VS-Follicular |
3.90640000003106E-06 |
| Tall-VS-Other |
4.947000E-01 |
| Tall-VS-Normal |
1.20370000000758E-06 |
| Follicular-VS-Other |
2.256400E-01 |
| Follicular-VS-Normal |
8.695000E-01 |
| Other-VS-Normal |
3.533200E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.3456999999949E-05 |
| Normal-vs-N1 |
1.151870E-04 |
| N0-vs-N1 |
2.368400E-01 |
|
|
